Flatiron Health real-world data (RWD) supported the U.S. Food and Drug Administration (FDA)’s recent approval of a new dosing regimen for ERBITUX® (Eli Lilly and Company’s cetuximab) that can have a direct positive impact on the lives of patients with metastatic colorectal cancer (CRC) or squamous cell carcinoma of the head Read more…
A new study, led by the University of Glasgow and published in The Lancet, has compared the three main ways anticancer treatment is given to patients when administered via a central vein. Hickman-type tunnelled catheters (Hickman), peripherally inserted central catheters (PICCs), and totally implanted ports (PORTs) are used to deliver Read more…
People with heart failure may live for many years and should continue to get regular cancer screenings, experts say. People with heart failure may be at increased risk for cancer. Cancer patients are usually monitored for heart failure because some cancer drugs can damage the heart. Now a new study Read more…
The US Food and Drug Administration (FDA) on Wednesday released draft guidance to help sponsors establish the effectiveness and safety of gonadotropin-releasing hormone (GnRH) analogues for treating advanced prostate cancer.GnRH agonists and antagonists are a mainstay for treating patients with prostate cancer, FDA says, noting that it is one of Read more…
Pancreatic cancer often kills people because they are diagnosed too late, after their tumors have spread. Other patients may die following the removal of harmless cysts that appear threatening amid a fog of imaging data and other clinical information. But a new artificial intelligence system unveiled Wednesday by doctors at Read more…
Regorafenib as monotherapy has demonstrated an overall survival benefit versus placebo in the pivotal Phase III CORRECT study and has shown activity irrespective of micro-satellite status in a retrospective analysis from this study, though with limited responses observed. Despite progress in the treatment of CRC, including the advance of effective immuno-oncology Read more…
Medicaid beneficiaries—particularly those from diverse communities that have been historically marginalized—have long been under-represented in clinical trials due to factors such as participation costs, time away from work, and travel expenses. Beginning January 2022, CMS will be required under the Clinical Treatment Act—part of the $2.3 trillion omnibus spending and relief Read more…
A federal court judge dismissed all claims against dozens of generic manufacturers and retailers in sprawling litigation over allegations that the Zantac heartburn pill may contain a carcinogen, although brand-name drug makers will continue to face more than 1,400 lawsuits over the issue. The ruling is the latest chapter in Read more…
Many newly approved cancer drugs fail to clearly communicate survival benefits associated with their use on the label, according to an analysis published Monday by JAMA Internal Medicine. Of the 125 drugs designed to treat cancer approved by the U.S. Food and Drug Administration between 2014 and 2018, 22 included evidence on their Read more…
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide Read more…